But the reality is not so simple
J Pharmacol Exp Ther 327 , 411424 (2008)
In another letter to the editor, Herbert et al
Disclosures: Dominique Larrey: SANOFI: Consultant, Dominique Larrey: Sanofi: Employee, Sanofi: Stock - publicly traded company, Claire Brulle-Wohlhueter: SANOFI: Stock options, Myriam Benamor: Nothing to Disclose, Jeffrey Chavin: Sanofi: Employee, Neda Razaz: Nothing to Disclose, Raphael Bejuit: Nothing to Disclose, Julien Dauriat: Sanofi: Consultant, Bayer: Consultant, Novartis: Consultant, Romane Pan: Sanofi: Consultant, Sanofi: Consultant, Servier: Consultant, Abbvie: Consultant, Neurochlore: Consultant, Thophile Reppelin: Nothing to Disclose, Sam Ekhtiari: Sanofi: Consultant, Nicolas Wagner: Sanofi: Consultant, Sanofi: Consultant, Fred Lublin: Sanofi: speaker, Avotres: stock options, Neuralight: stock options, Lapix therapeutic: stock options, Entelexo: stock options, novartis: source of funding for research, biogen: source of funding for research, Sanofi: source of funding for research, brainstorm cell therapeutics: source of funding for research, biogen: Consultant, EMD Serono: Consulting Agreements/Advisory Boards, Sanofi: Consulting Agreements/Advisory Boards, Biogen: Consulting Agreements/Advisory Boards, Novartis: Consulting Agreements/Advisory Boards, Janssen: Consulting Agreements/Advisory Boards, Roche/Genetech: Consulting Agreements/Advisory Boards, Horizen therapeutics/Amgen: Consulting Agreements/Advisory Boards, brainstorm cell therapeutics: Consulting Agreements/Advisory Boards, Mapi Pharma: Consulting Agreements/Advisory Boards, Mylan/Viatris: Consulting Agreements/Advisory Boards, Immunic: Consulting Agreements/Advisory Boards, Avotres: Consulting Agreements/Advisory Boards, Neuralight: Consulting Agreements/Advisory Boards, Neurogene: Consulting Agreements/Advisory Boards, Labcorp: Consulting Agreements/Advisory Boards, Entelexo biotherapeutics: Consulting Agreements/Advisory Boards, Setpoint medical: Consulting Agreements/Advisory Boards, Hexal/Sandoz: Consulting Agreements/Advisory Boards, Baim Institute: Consulting Agreements/Advisory Boards, Sudo biosciences: Consulting Agreements/Advisory Boards, Lapix therapeutics: Consulting Agreements/Advisory Boards, Biohaven Pharmaceuticals: Consulting Agreements/Advisory Boards, Abata therapeutics: Consulting Agreements/Advisory Boards, Cognito Therapeutics: Consulting Agreements/Advisory Boards, ImmPACT Bio: Consulting Agreements/Advisory Boards 1247 TRANSDILI: A DEEP TRANSFER LEARNING BASED PREDICTION FOR DRUG-INDUCED LIVER INJURY THROUGH LEVERAGING MOLECULAR STRUCTURE IMAGES Yue Li 1 Bingyan Liu 2 Yuanchun Guo 2 Jinyan Deng 1 Yi Guo 1 Hongbo Du 1 , 1 Dongzhimen Hospital, Beijing University of Chinese Medicine, 2 Beijing University of Posts and Telecommunication Background: Drug- induced liver injury (DILI) poses a global threat to acute liver failure
Its important to note that individual results can vary, and patience is key when using any skincare treatment for hyperpigmentation
10.1016/j.jinorgbio.2008.11.003 J
